Ryan & Maniskas, LLP Announces Investigation of Cornerstone Therapeutics Inc.
WAYNE, Pa., Sept. 17, 2013
WAYNE, Pa., Sept. 17, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP is
investigating potential claims against the board of directors of Cornerstone
Therapeutics Inc. ("Cornerstone" or the "Company") (NASDAQ: CRTX) concerning
possible breaches of fiduciary duty and other violations of law related to the
Company's efforts to sell the Company to Chiesi Farmaceutici S.p.A. in a
transaction valued at approximately $107 million.
(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO )
Under the terms of the agreement, shareholders of Cornerstone will receive
$9.50 per share in cash for each share of Cornerstone they own.
If you own shares of Cornerstone and would like to learn more about these
claims or if you wish to discuss these matters and have any questions
concerning this announcement or your rights, contact Richard A. Maniskas,
Esquire toll-free at (877) 316-3218 or to sign up online, visit:
www.rmclasslaw.com/cases/crtx. You may also email Mr. Maniskas at
Our investigation concerns possible breaches of fiduciary duty and other
violations of state law by Cornerstone's Board of Directors for not acting in
the Company's shareholders' best interests in connection with the sale
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan &
Maniskas, LLP is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal courts
nationwide. To learn more about the class action process, please visit:
CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
SOURCE Ryan & Maniskas, LLP
Press spacebar to pause and continue. Press esc to stop.